Prevalence and Histopathological Findings of Endometrioid Carcinoma and Associated Risk Factors: A Cross-Sectional Study: Prevalence and Histopathology of Endometrioid Carcinoma

Shagufta Nasir Pervez; Muhammad Junaid; Shaista Alam; Farhan Abbas Baloch; Pordil Khan; Noushad Bibi

doi:10.54393/pjhs.v5i11.2320

Authors

Shagufta Nasir Pervez Department of Pathology, Khyber Girls Medical College, Hayatabad Medical Complex, Peshawar, Pakistan
Muhammad Junaid Department of Rheumatology, University Hospital Waterford, County Waterford, Ireland
Shaista Alam Department of Microbiology and Pathology, Pak International Medical College, Peshawar, Pakistan
Farhan Abbas Baloch Department of Pathology, Pak International Medical College, Peshawar, Pakistan
Pordil Khan Department of Histopathology, Khyber Medical College, Peshawar, Pakistan
Noushad Bibi Department of Gynaecology, District Headquarter Hospital, Swabi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i11.2320

Keywords:

Endometrioid Carcinoma, Ovarian Cancer, Parity, Menopausal Status

Abstract

Ovarian cancer ranks as the seventh most frequently diagnosed malignancy among women worldwide. Endometrioid carcinoma, a type of proliferative endometrial tumor, accounts for approximately 15% of epithelial ovarian cancers, making it the third most common subtype. Objective: To investigate the relationship between Endometrioid Carcinoma and potential risk factors, including demographic, reproductive, and lifestyle factors. Methods: A cross-sectional study was conducted at Hayatabad Medical Complex's Department of Pathology from January 1 to December 31, 2023. The study analyzed 139 ovarian tumor specimens confirmed through histopathology. Statistical analysis using SPSS version 26 identified significant associations between variables using Chi-square tests and logistic regression, with a significance level of p < 0.05. Results: A total of 139 ovarian specimens with the patient's mean age (45.34 years) with the highest prevalence of endometrioid carcinoma observed in women aged 40-49 and 60 years and above. The prevalence of endometrioid carcinoma was about 14.4% (n=20). A significant association was identified between parity and endometrioid carcinoma (p-value = <0.001). Menopausal status also showed a significant association, with postmenopausal women having a higher prevalence of endometrioid carcinoma. Logistic regression analysis indicated that age was a significant predictor of endometrioid carcinoma (p-value = 0.028). Conclusions: Significant association between nullipara and premenopausal women with endometrioid carcinoma, emphasizing the importance of considering parity and menopausal status as a risk factor for endometrioid carcinoma.

References

Pragathi Y, Pooja B, AS PA, Nischitha HL, Chandan K, Jain V. AN UPDATED REVIEW ON OVARIAN CANCER. International Journal of Current Innovations in Advanced Research. 2023 Mar: 24-9. doi: 10.47957/ijciar.v6i1.146.

Zhu C, Xu Z, Zhang T, Qian L, Xiao W, Wei H et al. Updates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinoma. Journal of Cancer. 2021 Feb; 12(8): 2295. doi: 10.7150/jca.53395.

Navaneethakrishnan N, Rangaraj RA, Sankaran A. Histopathological Patterns Of Ovarian Tumours-A Retrospective Study In A Tertiary Care Centre. International Journal Academic Medicine Pharmacy. 2024; 6(1): 1563-7.

Goyal D, Agrawal S, Gupta G, Gupta A. Benign ovarian tumours in a tertiary care hospital: A 10 year histopathological study. International Journal of Health Sciences. 2022 May: 9745-50. doi: 10.53730/ijhs.v6nS2.7549.

Köbel M and Kang EY. The evolution of ovarian carcinoma subclassification. Cancers. 2022 Jan; 14(2): 416. doi: 10.3390/cancers14020416.

McSweeney SE and Atri M. Chapter 30 - Malignant Ovarian Masses. In: Fielding JR, Brown DL, Thurmond AS, editors. Gynecologic Imaging. Philadelphia: W.B. Saunders; 2011; 453-69. doi: 10.1016/B978-1-4377-1575-0.10030-1.

Oprescu N, Ionescu CA, Dragan I, Fetecau AC, Said-Moldoveanu AL, Chircu-lescu RA. Adnexal masses in pregnancy: perinatal impact. Romanian Journal of Morphology and Embryology. 2018 Jan; 59(1): 153-8.

Choi JI, Park SB, Han BH, Kim YH, Lee YH, Park HJ et al. Imaging features of complex solid and multicystic ovarian lesions: proposed algorithm for differential diagnosis. Clinical Imaging. 2016 Jan; 40(1): 46-56. doi: 10.1016/j.clinimag.2015.06.008.

Wills E, Grenn EE, Orr III WS. Multiple Intraabdominal and Pelvic Cystadenomas From Ovarian Remnant Syndrome. The American Surgeon. 2022 Sep; 88(9): 2218-20. doi: 10.1177/00031348221091962.

Poon C and Rome R. Malignant extra‐ovarian endometriosis: A case series of ten patients and review of the literature. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2020 Aug; 60(4): 585-91. doi: 10.1111/ajo.13178.

Zhou L, Yao L, Dai L, Zhu H, Ye X, Wang S et al. Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study. Journal of Ovarian Research. 2021 Dec; 14: 1-2. doi: 10.1186/s13048-021-00804-1.

Mei J, Tian H, Huang HS, Hsu CF, Liou Y, Wu N et al. Cellular models of development of ovarian high‐grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis. Cell Proliferation. 2021 May; 54(5): e13029. doi: 10.1111/cpr.13029.

Ahmad Z, Idress R, Fatima S, Uddin N, Ahmed A, Minhas K et al. Commonest cancers in Pakistan-findings and histopathological perspective from a premier surgical pathology center in Pakistan. Asian Pacific Journal of Cancer Prevention. 2016; 17(3): 1061. doi: 10.7314/APJCP.2016.17.3.1061.

Kanwal M, Sarfraz T, Tariq H. Histopathological and Immunohistochemical Evaluation of Malignant Ovarian Tumours. Pakistan Armed Forces Medical Journal. 2024 Feb; 74(1). doi: 10.51253/pafmj.v74i1.5949.

Falzone L, Scandurra G, Lombardo V, Gattuso G, Lavoro A, Distefano AB et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer. International Journal of Oncology. 2021 Jul; 59(1): 1-4. doi: 10.3892/ijo.2021.5233.

Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Menopause Review/Przegląd Menopauzalny. 2023 Jun; 22(2): 93-104. doi: 10.5114/pm.2023.128661.

Ohya A and Fujinaga Y. Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice. Japanese Journal of Radiology. 2022 Dec; 40(12): 1213-34. doi: 10.1007/s11604-022-01321-x.

Masood M and Singh N. Endometrial carcinoma: changes to classification (WHO 2020). Diagnostic Histopathology. 2021 Dec; 27(12): 493-9. doi: 10.1016/j.mpdhp.2021.09.003.

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer biology & medicine. 2017 Feb; 14(1): 9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.

Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. Journal of Clinical Oncology. 2016 Aug; 34(24): 2888-98. doi: 10.1200/JCO.2016.66.8178.

Saeed Z, Mushtaq S, Akhtar N, Hassan U. Frequency Of Napsin A Positivity In Ovarian Clear Cell Carcinoma And Serous Carcinoma: Napsin A Positivity in Ovarian Clear Cell Carcinoma. Pakistan Armed Forces Medical Journal. 2018 Aug; 68(4): 723-28.